Researchers found that NIH funding for major US cancers does not consistently align with lethality, with highly fatal cancers such as pancreatic cancer and small-cell lung cancer receiving far less funding per estimated death than breast or prostate cancer. The study argues that incidence alone is not enough and that funding decisions should better incorporate mortality, survival, and mortality-to-incidence ratios.